Moderna

At our annual R&D Day yesterday, we announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline. For the latest episode of our #IRInsights series, Our CEO Stéphane Bancel, President Stephen Hoge and CFO Jamey Mock sat down to discuss their focus on delivering 10 new products to patients, pacing R&D investment, and building the Company’s commercial business. Watch the full video here: https://lnkd.in/eKeTsiqu

Over the past three years, Moderna’s robust pipeline has achieved milestones across multiple late-stage clinical trials, and its early-stage portfolio has produced proof-of-concept data with multiple candidates ready for pivotal studies. From developing treatments for unmet needs, to addressing global health threats - we're here to fight the big, intimidating, impossible-to-change problems. We're here to change #medicine. #ThisChangesEverything

We announced today program and financial updates demonstrating progress and strategic prioritization of our mRNA pipeline at our annual R&D Day event. The updates include data readouts in our respiratory vaccine portfolio and a revised financial framework. Read more: https://lnkd.in/escPMJpy

We announced today that Swissmedic has granted full marketing authorization for the use of our updated #COVID19 #vaccine in Switzerland targeting the SARS-CoV-2 variant JN.1. In Switzerland, COVID-19 vaccination is recommended in autumn for persons at an increased risk of developing a severe case of the illness.

We announced today that our manufacturing facility in Laval, Quebec, has been granted a Drug Establishment License (DEL) from Health Canada. This certification affirms the facility’s compliance with rigorous safety and quality standards, authorizing it to produce drug substance. This key milestone enables our Canadian manufacturing site to become fully operational, bringing the company closer to ensuring a reliable and onshore supply of #mRNA #vaccines within Canada. Learn more: https://lnkd.in/ejTChF8D

With updated #vaccines available and fall around the corner, a commonly asked question is why is it important to get vaccinated every year? ???? Watch the latest episode of #CoffeeBreakScience, featuring Preeti Sule, to find out! ??

We announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of our COVID-19 mRNA vaccine, targeting the SARS-CoV-2 variant JN.1. Learn more: https://lnkd.in/eZff4r3M

We are likely to encounter the #COVID19 virus again as we enter another respiratory virus season, and the gravity of your next COVID-19 episode depends on a variety of factors. Here are key things to keep in mind about repeat COVID infections as we approach the fall and winter months: https://lnkd.in/g6WEr76v

For Keke Wu, Senior Director of People Analytics at Moderna, her role isn't just about crunching numbers; it's about fostering an environment where every employee can thrive. Learn more about Keke's path to people analytics, and her changemaker journey at Moderna: https://lnkd.in/gAT4W6Px

We announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized our updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn vaccination program, which is prioritized for use in people at greatest risk of serious illness from COVID-19. Read more: https://lnkd.in/eNuqyJpJ